HeartBeat.bio focuses on cardiac drug development, utilizing human organoid technologies, hardware engineering, and artificial intelligence. The company's mission is to change the paradigm of this field.

HeartBeat.bio

HeartBeat.bio AG | 1,874 followers on LinkedIn. REINVENTING CARDIAC DRUG DISCOVERY | HeartBeat.bio (HBB) is an emerging TechBio company developing a next-generation drug discovery platform for heart diseases. Our so-called Cardioid Drug Discovery Platform is based on a proprietary iPSC-derived single and multi-chamber cardiac organoid model. We combine this unique human biology with state-of-the-art hardware solutions to industrialize the organoid cultivation and screening process as well as AI-supported software for high-content and big data analysis.

Invest AG - Private Equity

Ingomar Wiesinger

for Science and Humanity

Xian Zhang

Lead scientist for Assay Development and Data Science @HeartBeat.bio

Lokesh Pimpale

Chief Technology Officer at HeartBeat.bio AG | Innovative Screening

Florian Fuchs

HeartBeat.bio AG

Let's celebrate what we do best: partnerships. Join me at BIO-Europe, November 4–6, 2024, in Stockholm, Sweden, where the event marks 30 years of facilitating partnerships. Looking forward to welcome you. Register here: https://lnkd.in/ezDGX2sf Informa Connect

Thank you to Zefyron for mentioning HeartBeat.bio AG in their list of Austrian Biotech Innovators reshaping the future of drug discovery and healthcare. 😀

🌟We’re thrilled to kick off the Advanced Imaging and Organoid Technologies Meeting with an insightful keynote from Florian Fuchs of HeartBeat.bio AG . His talk, ‘Unleashing the Potential of 3D Biology in Automated High-Throughput Cardioids for Drug Discovery and Toxicity Testing,’ delves into the cutting-edge advancements in 3D biology. These innovations are set to revolutionize drug discovery and testing, enabling faster, more accurate results. Stay tuned for more groundbreaking discussions as we explore the future of science and innovation! #ImgUserMeetingMD24 #Imaging #3dbiology #drugdiscovery #drugdevelopment

Molecular Devices

If you are attending the Heart Days of the German Society of Cardiology in Hamburg today, be sure not to miss today's presentation by HeartBeat.bio AG . The presentation starts at 1:50 p.m. in the Plaza Room as part of the eCardiology session chaired by Benjamin Meder. https://lnkd.in/e2dVAWRZ

Another great example of the power of human organoids in drug research and development and their increasing application in the pharmaceutical industry. Thanks to Kimberly Homan and Genentech for sharing their experience with us. It's definitely worth listening to! #stemcell #stemcells #organoids #drugdiscovery #drugscreening #drugsafety #toxicology #drugdevelopment #highthroughput

Thank you to LISAvienna for organizing the SLAS (Society for Laboratory Automation and Screening) Austrian Community Meet-up and congratulations for bringing the SLAS Europe Conference & Exhibition to Vienna in 2026. 👍🥳

Many thanks to Startup Stash for honoring HeartBeat.bio AG as one of the Top 10 Austrian Startups to Watch in 2024. #startups #venturecapital #organoids #drugdiscovery #drugscreening #drugdevelopment #cardiac #cardiology #cardiovasculardisease #heartfailure #heartdisease

📢 Speaker Update! Florian Fuchs from HeartBeat.bio AG will be sharing groundbreaking insights into cardiac organoid technology for drug discovery and safety testing at our upcoming event. Don't miss this chance to learn how HeartBeat.bio is advancing cardiac research and transforming drug development! 🌟 📅 1st of October | Free Admission Limited spots available—reserve your spot now! #Organoids #DrugDiscovery #Cardiotoxicity #HeartResearch #Innovation #Networking

This year's Heart Days of the German Cardiac Society will take place from September 26 to 28 at the Congress Center in Hamburg. Our CSO Dr. Pablo Hofbauer and Senior Scientist Dr. Ruben van Helden , will present HeartBeat.bio AG 's unique Cardioid-based and AI-assisted cardiac drug discovery platform on Thursday, September 26, 2024. We look forward to many meetings and discussions with scientists and clinicians interested in collaborative drug discovery projects related to cardiomyopathies, myocardial infarction, and cardio-protection/remodeling/regeneration. Interested participants are welcome to contact us at office@heartbeat.bio to arrange on-site meetups. #3Dmodels #organoids #cardiology #cardiomyopathies #cardiacdiseases #cardiovasculardiseases #myocardialinfarction #cardiacremodeling #cardiacregeneration #cardioprotection #drugdiscovery

Euro

CrUX Dataset

CrUX Top 50m

Scientist

Nastasja Grdseloff

Michael Krebs

CEO & Co-Founder

Austria Companies (Top 10K)

European Union (EU) Startups (Top 10K)

Biotechnology Companies (Top 10K)

Medical Companies With More Than 10 Employees (Top 10K)

HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.

aws Gründungsfonds

i&i Biotech Fund

INVEST AG

Tensor Ventures

Seed Round - HeartBeat.bio

red-stars.com

Vienna

Wien

Austria

Europe

New heart organoid model could revolutionize drug ...

Vienna-based HeartBeat.bio raises €4.5 million to develop 3D ...

HeartBeat.bio Closes € 4.5M Pre-Series A Funding Round

Vienna-based HeartBeat.bio raises €4.5 million to develop 3D human tissue-based drug discovery platform for heart ...

Austrian biotech HeartBeat.bio raises €4.5M pre-Series A round

Austrian biotech HeartBeat.bio secures €4.5M for cardioid drug discovery platform

A high throughput screening platform for cardiotoxicity testing and cardiac drug discovery, combining hardware solutions, 3D heart tissue models, functional assays, and AI-based data analysis.

iPSC-derived, multi-cellular 3D cardiac tissue models that replicate human heart physiology for drug discovery.

An automated system for generating, acquiring, and quality controlling Cardioids, integrated with AI for drug screening.

Scalable disease models for drug-induced and genetic cardiomyopathies, myocardial infarction, and fibrosis.

news impact assignment basic	general
public peers	general	Nov 16, 2024 10:38 PM	3bcb53d4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 16, 2024 10:38 PM	fb21110d
crunchbase trigger	general	Nov 16, 2024 10:38 PM	11609701
crunchbase profile	general	Nov 16, 2024 10:48 PM	d77a848d
li profile	general	Nov 16, 2024 10:38 PM	906048bf
translate crunchbase fundingrounds	general	Nov 16, 2024 11:08 PM	8860ae7a
peers	general	Nov 16, 2024 10:38 PM	1fd13ff8
news basic	general	Nov 16, 2024 10:38 PM	f4c6a417
bundesanzeiger	filings
financials download nd	financials
private financials	financials

HEAR

BIO:HEARTBEAT

HeartBeat.bio